Search

Author/Creator Coleman, Robert L

1. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. (20th October 2022)

Authors:
Coleman, Robert L; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; O'Malley, David M; Goble,...
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A226
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (20th October 2022)

Authors:
Concin, Nicole; Monk, Bradley J; Mirza, Mansoor Raza; Coleman, Robert L; Ray-Coquard, Isabelle; Pothuri, Bhavana; Baurain, Jean-Francois; Alejandro Perez-Fidalgo, J; Cibula, David; Saverse, Antonella; Banerjee, Susana; Madry, Radek; Marth, Christian; Putiri, Emily; Barrett, Jamie; DeMars, Leslie;...
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. (20th October 2022)

Authors:
Colombo, Nicoletta; Coleman, Robert L; Wu, Xiaohua; Köse, Fatih; Wenham, Robert M; Sebastianelli, Alexandra; Hasegawa, Kosei; Zsiros, Emese; Rouge, Thibault De La Motte; Bidziński, Mariusz; McNeish, Iain; Sehouli, Jalid; Korach, Jacob; Debruyne, Philip R; Kim, Jae-Weon; de Melo, Andréia C; Peng, ...
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A251
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. (20th October 2022)

Authors:
Oaknin, Ana; Lorusso, Domenica; Oza, Amit; Colombo, Nicoletta; van Gorp, Toon; O'Malley, David; Banerjee, Susana; Murphy, Conleth; Harter, Philipp; Konecny, Gottfried; Kaminsky, Marie-Christine; Method, Michael; Wang, Jiuzhou; Coleman, Robert L; Birrer, Michael; Matulonis, Ursula; Moore, Kathleen
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A251
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68). (20th October 2022)

Authors:
Herzog, Thomas J; Moore, Kathleen; Konstantinopoulos, Panagiotis A; Gilbert, Lucy; Hays, John L; Monk, Bradley J; O'Malley, David M; Barlin, Joyce N; Graham, Julie R; Desai, Monali; Wang, Yan; Du, Yangchun; Dalal, Rita; Coleman, Robert L; Sehouli, Jalid
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A255
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 366 Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer. (4th December 2020)

Authors:
Lorusso, Domenica; Guy, Holly; Hamilton, Jean; Samyshkin, Yevgeniy; Travers, Karin; Hawkes, Carol; Coleman, Robert L
Journal:
International journal of gynecological cancer
Issue:
Volume 30(2020)Supplement 4
Page Start:
A71
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 387 ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). (4th December 2020)

Authors:
Mirza, Mansoor R; Coleman, Robert L; Hanker, Lars; Slomovitz, Brian; Valabrega, Giorgio; Im, Ellie; Walker, Monica; Powell, Matthew
Journal:
International journal of gynecological cancer
Issue:
Volume 30(2020)Supplement 4
Page Start:
A112
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. Issue 4 (7th October 2019)

Authors:
Pishvaian, Michael J; Blais, Edik M; Bender, R Joseph; Rao, Shruti; Boca, Simina M; Chung, Vincent; Hendifar, Andrew E; Mikhail, Sam; Sohal, Davendra P S; Pohlmann, Paula R; Moore, Kathleen N; He, Kai; Monk, Bradley J; Coleman, Robert L; Herzog, Thomas J; Halverson, David D; DeArbeloa, Patricia; ...
Journal:
JAMIA open
Issue:
Volume 2:Issue 4(2019)
Page Start:
505
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗